[The characteristics of a parkinsonian syndrome induced in an experiment by a deficiency of nigrostriatal dopamine and by stimulation of the cholinergic neurons of the caudate nucleus].
An experimental parkinsonian syndrome (PS) was induced by systemic administration of MPTP or oxotremorine, by intranigral administration of MPP+ or injection of acetyl choline and proserine into the rostral part of both caudate nuclei. The development of extrapyramidal disorders was studied simultaneously with EEG recording. The electric activity (EA) was recorded in the sensorimotor cortex, caudate nuclei, ventrolateral nuclei of the thalami, substantia nigra and globus pallidus. Tremor, oligokinesia and rigidity were characterized by the appearance of paroxysmal activity on EA with high amplitude of slow and rapid waves. The data obtained allow us to conclude that PS neuropathophysiological basis is the formation of the generator of pathologically enhanced excitation (GPEE) in the caudate nuclei. It was found that akinesia-rigidity syndromes were observed in the rats with both MPTP and MPP(+)-induced PS. Tremor was observed after administration of oxotremorine or acetyl choline with proserine more often than after treatment with MPTP or MPP+. Some peculiarities of the GPEE activity in these forms of PS were observed. Also, there is dissociation in effects of antiparkinsonian drugs in different forms of PS.
Kryzhanovskiĭ
G N
GN
Atadzhanov
M A
MA
Voronina
T A
TA
Nerobkova
L N
LN
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology; D015655:1-Methyl-4-phenylpyridinium / Q000494:pharmacology; D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D002421:Caudate Nucleus / Q000187:drug effects* / Q000502:physiology; D003342:Corpus Striatum / Q000187:drug effects* / Q000503:physiopathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000172:deficiency*; D018492:Dopamine Antagonists; D004569:Electroencephalography / Q000187:drug effects; D008297:Male; D009388:Neostigmine / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D010095:Oxotremorine / Q000494:pharmacology; D010302:Parkinson Disease, Secondary / Q000209:etiology* / Q000503:physiopathology; D051381:Rats; D011950:Receptors, Cholinergic / Q000187:drug effects* / Q000502:physiology; D013378:Substantia Nigra / Q000187:drug effects* / Q000503:physiopathology
D018492:Dopamine Antagonists; D011950:Receptors, Cholinergic; D009388:Neostigmine; D010095:Oxotremorine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000109:Acetylcholine; D015655:1-Methyl-4-phenylpyridinium; D004298:Dopamine
Osobennosti parkinsonicheskogo sindroma, vyzvannogo v éksperimente defitsitom nigrostriarnogo dofamina i stimuliatsieĭ kholinergicheskikh neĭronov khvostatykh iader.